Literature DB >> 22149553

Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) [Prevenar 13(®)]: profile report.

Sean T Duggan1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22149553     DOI： 10.2165/11207010-000000000-00000

Source DB:  PubMed          Journal:  Paediatr Drugs        ISSN： 1174-5878            Impact factor:   3.022


× No keyword cloud information.
  14 in total

Review 1.  Typing of Streptococcus pneumoniae: past, present, and future.

Authors:  J Henrichsen
Journal:  Am J Med       Date:  1999-07-26       Impact factor: 4.965

2.  Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I.

Authors:  W P Hausdorff; J Bryant; P R Paradiso; G R Siber
Journal:  Clin Infect Dis       Date:  2000-01       Impact factor: 9.079

3.  Indirect effects associated with widespread vaccination of infants with heptavalent pneumococcal conjugate vaccine (PCV7; Prevnar).

Authors:  Daniel J Isaacman; Mark A Fletcher; Bernard Fritzell; Vincent Ciuryla; Jennifer Schranz
Journal:  Vaccine       Date:  2006-09-18       Impact factor: 3.641

Review 4.  The potential indirect effect of conjugate pneumococcal vaccines.

Authors:  Katherine L O'Brien; Ron Dagan
Journal:  Vaccine       Date:  2003-05-16       Impact factor: 3.641

Review 5.  Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) [prevenar 13®].

Authors:  Sean T Duggan
Journal:  Drugs       Date:  2010-10-22       Impact factor: 9.546

6.  Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany.

Authors:  Dorothee M Kieninger; Kathrin Kueper; Katrin Steul; Christine Juergens; Norbert Ahlers; Sherryl Baker; Kathrin U Jansen; Carmel Devlin; William C Gruber; Emilio A Emini; Daniel A Scott
Journal:  Vaccine       Date:  2010-04-22       Impact factor: 3.641

7.  Effect of pneumococcal conjugate vaccine on pneumococcal meningitis.

Authors:  Heather E Hsu; Kathleen A Shutt; Matthew R Moore; Bernard W Beall; Nancy M Bennett; Allen S Craig; Monica M Farley; James H Jorgensen; Catherine A Lexau; Susan Petit; Arthur Reingold; William Schaffner; Ann Thomas; Cynthia G Whitney; Lee H Harrison
Journal:  N Engl J Med       Date:  2009-01-15       Impact factor: 91.245

8.  Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine.

Authors:  Cynthia G Whitney; Monica M Farley; James Hadler; Lee H Harrison; Nancy M Bennett; Ruth Lynfield; Arthur Reingold; Paul R Cieslak; Tamara Pilishvili; Delois Jackson; Richard R Facklam; James H Jorgensen; Anne Schuchat
Journal:  N Engl J Med       Date:  2003-05-01       Impact factor: 91.245

9.  Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal colonization among unvaccinated household members.

Authors:  Eugene V Millar; James P Watt; Melinda A Bronsdon; Jean Dallas; Raymond Reid; Mathuram Santosham; Katherine L O'Brien
Journal:  Clin Infect Dis       Date:  2008-10-15       Impact factor: 9.079

10.  Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004.

Authors:  Lauri A Hicks; Lee H Harrison; Brendan Flannery; James L Hadler; William Schaffner; Allen S Craig; Delois Jackson; Ann Thomas; Bernard Beall; Ruth Lynfield; Arthur Reingold; Monica M Farley; Cynthia G Whitney
Journal:  J Infect Dis       Date:  2007-10-04       Impact factor: 5.226
View more
  1 in total

1.  Pneumococcal serotype-specific antibodies persist through early childhood after infant immunization: follow-up from a randomized controlled trial.

Authors:  Johannes Trück; Matthew D Snape; Florencia Tatangeli; Merryn Voysey; Ly-Mee Yu; Saul N Faust; Paul T Heath; Adam Finn; Andrew J Pollard
Journal:  PLoS One       Date:  2014-03-11       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.